Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

667
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
667
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.5K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.5K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.5K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.5K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

600
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
600
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

575
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
575

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical controversies in the management of candidemia in adults and children.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same author

Combination treatment with synthetic gRNA/Cas12a and gRNA/Cas9 ribonucleoproteins disrupts HIV replication and expression.

iScience·2026
Same author

Need for More HIV-Trained Pharmacists due to Unmet Needs and Expanding Opportunities: An Opinion of the HIV Practice and Research Network of the American College of Clinical Pharmacy.

Journal of the American College of Clinical Pharmacy : JACCP·2026
Same author

Extracellular Vesicles: A Comprehensive Review of Their Origins, Functions, and Therapeutic Potential.

Biomedicines·2026
Same author

Precision dosing of systemic antifungals in adults: therapeutic drug monitoring, empiric dose optimization and barriers to implementation.

The Journal of antimicrobial chemotherapy·2026
Same author

Suppression of HBV replication and expression by CRISPR/Cas9 ribonucleoproteins.

Antiviral research·2025

Related Experiment Video

Updated: Jan 31, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.4K

HIV Integrase Inhibitor Pharmacogenetics: An Exploratory Study.

Derek E Murrell1,2, David B Cluck2,3, Jonathan P Moorman2,4

  • 1Department of Pharmaceutical Sciences, Gatton College of Pharmacy, East Tennessee State University, Box 70594, Johnson City, TN, 37614-1708, USA.

Clinical Drug Investigation
|January 10, 2019
PubMed
Summary

This study explored how genetic variations (SNPs) impact treatment outcomes for HIV patients on integrase strand transfer inhibitors (INSTIs). Some single-nucleotide polymorphisms were associated with adverse events, suggesting a role for pharmacogenetics in HIV therapy.

More Related Videos

Measurement of In Vitro Integration Activity of HIV-1 Preintegration Complexes
10:34

Measurement of In Vitro Integration Activity of HIV-1 Preintegration Complexes

Published on: February 22, 2017

8.0K
A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
07:22

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion

Published on: August 14, 2018

7.0K

Related Experiment Videos

Last Updated: Jan 31, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.4K
Measurement of In Vitro Integration Activity of HIV-1 Preintegration Complexes
10:34

Measurement of In Vitro Integration Activity of HIV-1 Preintegration Complexes

Published on: February 22, 2017

8.0K
A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
07:22

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion

Published on: August 14, 2018

7.0K

Area of Science:

  • Pharmacogenomics
  • HIV Therapeutics
  • Clinical Pharmacology

Background:

  • Integrase strand transfer inhibitors (INSTIs) are crucial for HIV treatment.
  • Individual variability in side effect occurrence necessitates further investigation.
  • Understanding genetic influences can optimize INSTI therapy.

Purpose of the Study:

  • To explore associations between single-nucleotide polymorphisms (SNPs) and clinical outcomes in HIV patients on INSTIs.
  • To examine the impact of SNPs on drug concentration, adverse events, and treatment efficacy.
  • To identify potential pharmacogenetic markers for personalized HIV management.

Main Methods:

  • Adult HIV patients on INSTI-based regimens were recruited and genotyped.
  • Analysis involved multiple linear or logistic regression with relevant covariates.
  • Statistical significance was set at p < 0.05 to detect associations between genetic variants and clinical data.

Main Results:

  • A sample of 88 participants, predominantly Caucasian males, was analyzed.
  • Abnormal dream occurrence showed a statistically significant difference between regimens (p=0.028).
  • Several SNPs were associated with adverse event profiles when INSTI regimens were grouped.

Conclusions:

  • Exploratory findings suggest a need for further research into factors affecting HIV patient outcomes.
  • Associations between SNPs and adverse events warrant confirmation in larger cohorts.
  • Future studies may elucidate pharmacogenetic mechanisms underlying INSTI tolerability and efficacy.